News

  • 27 June 2018

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and bowel dysfunction, announced today that it has completed enrollment for ARTISAN-SNM, its pivotal clinical study designed to gain U.S. Food & Drug Administration (FDA) approval in the United States.

  • 25 June 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces that it has expanded the license agreement for its Vaxiclase platform with the Serum Institute of India (SIIPL), the world's largest vaccine manufacturer, to include the developed world in their addressable markets. The initial agreement, signed in 2015, covered emerging pharmaceutical markets.

  • 19 June 2018

    JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment and implantations associated with the CE Mark study of its next generation JenaValve Pericardial TAVR System using the Coronatix Transfemoral Delivery Catheter for the percutaneous treatment of patients with symptomatic, severe aortic regurgitation (AR). The JenaValve Pericardial TAVR System is an investigational device in the United States and internationally.

  • 14 June 2018

    Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB200, LLC, a portfolio company of Bravos Biosciences, LLC, has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected monoclonal antibodies (mAbs) targeting K. pneumoniae that were discovered by Arsanis in its ASN300 program, including lead preclinical development candidate, ASN-5. In April 2018, Arsanis entered into a similar agreement for its ASN200 program, targeting E. coli, with Bravos Biosciences subsidiary BB100, LLC.

  • 4 June 2018

    Patients with metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience a durable tumour response with a median follow up of 19.1 months, without yet reaching median overall survival (OS), according to new Phase I research to be presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  IMCgp100 is the wholly-owned, lead programme from Immunocore Limited, a leading T-cell receptor (TCR) company focused on delivering first-in-class biological therapies that transform lives.